ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2688

Methotrexate Dose Has Minimal Effects On Methotrexate-Related Toxicity In Patients With Early Rheumatoid Arthritis Treated In Combination With Adalimumab – Results Of Concerto Trial

Gerd Burmester1, Alan J. Kivitz2, Ronald F. van Vollenhoven3, Stefan Florentinus4, Piyalal M. Karunaratne5, Hartmut Kupper6, Maxime Dougados7 and Roy Fleischmann8, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Altoona Center for Clinical Research, Duncansville, PA, 3The Karolinska Institute, Stockholm, Sweden, 4AbbVie, Rungis, France, 5AbbVie Inc., North Chicago, IL, 6AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, 7Hopital Cochin, René Descartes University, Paris, France, 8University of Texas Southwestern Medical Center, Dallas, TX

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adalimumab, methotrexate (MTX) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Novel Treatment Strategies in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Adalimumab is usually used in combination with 15-20 mg methotrexate (MTX) weekly in early rheumatoid arthritis (RA). Lower doses of MTX in combination with biologics have not been evaluated in controlled clinical trials. The objective of this study was to evaluate the MTX dose-response of MTX-related toxicities in patients (pts) with early RA receiving ADA in combination with MTX.

Methods: CONCERTO was a 26-week (wk), phase 3, double-blind, parallel-arm study in MTX-naive pts with active RA <1 year in duration. Pts were randomized 1:1:1:1 to open-label ADA 40 mg every other wk + blinded weekly oral MTX doses of 2.5, 5, 10, or 20 mg. All pts took 5 mg folic acid weekly throughout the study. Pts in the 20 mg arm started with 10 mg MTX, with bi-weekly increases of 2.5 mg through wk 8. MTX-toxicity related adverse events (AEs) were defined according to MTX prescribing information and recorded as AEs at each visit through wk 26. Laboratory data were summarized through wk 26.

Results: Of the 395 randomized pts, 358 (91%) completed 26 wks. The safety population included 98, 100, 99, and 98 pts in the 2.5, 5, 10, and 20 mg arms, respectively. 9 pts (2.3%) discontinued study drug due to an AE that was not necessarily MTX-related. Of the total population, the percentage of pts with any AE was 62, 59, 67, and 69%, any serious AE was 5, 2, 3 and 7%, and any infection was 20, 17, 24, and 35% in the 2.5, 5, 10, and 20 mg arms, respectively. Two infections in the 5 mg arm were serious AEs, appendicitis and sepsis, but did not result in study discontinuation and were not associated with MTX. The overall incidence of MTX-related AEs was low (Table). Infection and abnormal hair loss appeared to have a MTX dose relationship. No differences in mean change from baseline in hematocrit, neutrophil count, platelet count, ALT, or AST values were observed at wk 26 among the 4 doses of MTX. The percentage of pts with ALT values >upper limit of normal (ULN) that were associated with MTX at wk 26 were 3, 1, 6, and 6% in the 2.5, 5, 10, and 20 mg arms, respectively. Regarding AST, 4, 0, 3, and 3% in the 2.5, 5, 10, and 20 mg arms, respectively, had AST values >ULN.

Table.  Adverse Events Reported by Investigators to be Associated with MTX

 

ADA+2.5 mg MTX

ADA+5 mg MTX

ADA+10 mg MTX

ADA+20 mg MTX

Total

 

 (N=98)

 (N=100)

 (N=99)

(N=98) 

 (N=395)

 

 n (%)

n (%)

n (%)

n (%)

 n (%)

Infection

6 (6.1)

7 (7.0)

11 (11.1)

13 (13.3)

37 (9.4)

Nausea &/or vomiting

6 (6.1)

3 (3.0)

13 (13.1)

8 (8.2)

30 (7.6)

Stomach pain/discomfort

5 (5.1)

4 (4.0)

7 (7.1)

7 (7.1)

23 (5.8)

Abnormal hair loss

1 (1.0)

5 (5.0)

5 (5.1)

8 (8.2)

19 (4.8)

Excessive fatigue &/or malaise

4 (4.1)

1 (1.0)

3 (3.0)

2 (2.0)

10 (2.5)

Dizziness

4 (4.1)

0

4 (4.0)

1 (1.0)

9 (2.3)

Oral ulcers

0

1 (1.0)

5 (5.1)

2 (2.0)

8 (2.0)

Fever &/or chills

0

1 (1.0)

3 (3.0)

0

4 (1.0)

Conclusion: Overall, the combination of ADA plus varying doses of MTX was well tolerated, and MTX-related AEs were infrequent. The frequency of infections and abnormal hair loss appeared to have a MTX-dose relationship. Serious infections were very rare and had no relationship to MTX. No differences in mean change from baseline in blood cell counts or transaminases were observed at wk 26 among the 4 doses of MTX.


Disclosure:

G. Burmester,

AbbVie, Essex/Schering-Plough, Novartis, Roche, and Wyeth,

2,

AbbVie, Essex/Schering-Plough, Novartis, Roche, and Wyeth,

5,

AbbVie, Essex/Schering-Plough, Novartis, Roche, and Wyeth,

8;

A. J. Kivitz,

AbbVie, Amgen, AstraZeneca, BMS, Celgene, Genentech, Janssen, Pfizer, and UCB,

2,

AbbVie, BMS, Genentech, Pfizer, and UCB,

5,

Pfizer and BMS,

8;

R. F. van Vollenhoven,

AbbVie, BMS, GSK, Human Genome Sciences, Merck, Pfizer, Roche, and UCB,

2,

AbbVie, BMS, GSK, Human Genome Sciences, Merck, Pfizer, Roche, and UCB,

5;

S. Florentinus,

AbbVie,

1,

AbbVie,

3;

P. M. Karunaratne,

AbbVie,

1,

AbbVie,

3;

H. Kupper,

AbbVie,

1,

AbbVie,

3;

M. Dougados,

AbbVie, BMS, Merck, Novartis, Pfizer, Sanofi-Aventis, and UCB,

2,

AbbVie, BMS, Merck, Novartis, Pfizer, Sanofi-Aventis, and UCB,

5;

R. Fleischmann,

AbbVie, Pfizer, Merck, Roche, UCB, Celgene, Amgen, Astra-Zeneca, BMS, Janssen, Lilly, and Novartis,

2,

AbbVie, Pfizer, Merck, Roche, UCB, Celgene, Amgen, Astra-Zeneca, BMS, Janssen, Lilly, and Novartis,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-dose-has-minimal-effects-on-methotrexate-related-toxicity-in-patients-with-early-rheumatoid-arthritis-treated-in-combination-with-adalimumab-results-of-concerto-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology